News and Updates
Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
FAQ document for DIGITAL-EUROHPC-JU-2023-AISC-03
The EuroHPC Joint Undertaking has published an FAQ document containing relevant clarifications for call DIGITAL-EUROHPC-JU-2023-AISC-03.
The FAQ document can be found here.
Related News
|
2024-12-09
|
1 month ago |
New call: European Master for HPC |
|
2024-09-11
|
4 months ago |
Calls for expressions of interest: Hosting entities for AI factories |
|
2024-09-06
|
4 months ago |
Consultations on Digital Europe programme |
|
2024-07-31
|
5 months ago |
EuroHPC JU to create AI Factories |
|
2024-07-31
|
5 months ago |
Digital Europe Dashboard is now live |
|
2024-07-16
|
6 months ago |
JUPITER - first European Exascale computer acquired through Digital Europe |
|
2024-07-12
|
6 months ago |
Open call for SMEs and start-ups: experiments with supercomputers and scaling up gene... |
|
2023-11-30
|
1 year ago |
Large AI Grand Challenge (AI BOOST) |
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Latest News
1517 articles available search in articlesTestimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
